OS Therapies Inc

OSTX · NYSE · SIC 2834: Pharmaceutical Preparations
58
SEC Filings

Business Summary

. Overview and Mission OS Therapies Incorporated (OS Therapies, the Company, we, our or us) is a clinical stage biopharmaceutical company focused on the identification, development and commercialization of treatments for Osteosarcoma (OS) and other solid tumors. Our mission is to address the significant need for new treatments in cancers of the bone in children and young adults. Osteosarcoma is an extremely challenging and often aggressive cancer that has particular treatment challenges due to i...

Next Earnings

Q2 FY2026 — expected 2026-09-17

Key Facts from Earnings Calls

TypeSubjectDetailQuarter
topic_mentionOSTXdiscussed_in_filing Cybersecurity
topic_mentionOSTXdiscussed_in_filing Trusted Computing
topic_mentionOSTXdiscussed_in_filing Blockchain & Crypto
topic_mentionOSTXdiscussed_in_filing Capital Expenditure
topic_mentionOSTXdiscussed_in_filing Regulation
topic_mentionOSTXdiscussed_in_filing Healthcare & Bio
topic_mentionOSTXdiscussed_in_filing Platform & Ecosystem
topic_mentionOSTXdiscussed_in_filing Cybersecurity
topic_mentionOSTXdiscussed_in_filing Trusted Computing
topic_mentionOSTXdiscussed_in_filing Blockchain & Crypto
topic_mentionOSTXdiscussed_in_filing Capital Expenditure
topic_mentionOSTXdiscussed_in_filing Regulation
topic_mentionOSTXdiscussed_in_filing Healthcare & Bio
topic_mentionOSTXdiscussed_in_filing Platform & Ecosystem
topic_mentionOSTXdiscussed_in_filing Cybersecurity
topic_mentionOSTXdiscussed_in_filing Trusted Computing
topic_mentionOSTXdiscussed_in_filing Blockchain & Crypto
topic_mentionOSTXdiscussed_in_filing Capital Expenditure
topic_mentionOSTXdiscussed_in_filing Regulation
topic_mentionOSTXdiscussed_in_filing Healthcare & Bio

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2026-03-312025-12-310001213900-26-036629EDGAR80K words
2025-03-312024-12-310001213900-25-026238EDGAR—

Quarterly Reports (10-Q)

FiledPeriodAccessionSourceFull Text
2025-11-142025-09-300001213900-25-110829EDGAR33K words
2025-08-182025-06-300001213900-25-077916EDGAR—
2025-05-152025-03-310001213900-25-044336EDGAR—
2024-11-152024-09-300001213900-24-098760EDGAR—
2024-08-142024-06-300001213900-24-069063EDGAR—
2024-05-202024-03-310001213900-24-045141EDGAR—

Recent Current Reports (8-K)

FiledAccessionSourceFull Text
2026-04-020001213900-26-039529EDGAR23K words
2026-03-310001213900-26-037476EDGAR—
2026-03-060001213900-26-024726EDGAR—
2026-02-130001213900-26-016408EDGAR—
2026-01-120001213900-26-003166EDGAR—
2025-10-210001213900-25-100821EDGAR—
2025-10-170001213900-25-100019EDGAR—
2025-09-300001213900-25-093936EDGAR—
2025-09-020001213900-25-083396EDGAR—
2025-08-260001213900-25-080484EDGAR—

58 total filings indexed. 40 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Sector Peers

SXTP — 60 DEGREES PHARMACEUTICALS, INC. ABT — ABBOTT LABORATORIES ABEO — ABEONA THERAPEUTICS INC. ABVC — ABVC BIOPHARMA, INC. ACAD — ACADIA PHARMACEUTICALS INC ACTU — ACTUATE THERAPEUTICS, INC. ADCT — ADC Therapeutics SA ADIL — ADIAL PHARMACEUTICALS, INC.

Company Identity

CIK0001795091
TickerOSTX
ExchangeNYSE
SIC2834: Pharmaceutical Preparations
IncorporatedDE

Get More Data

This is the free public profile. For structured JSON with full provenance chain, use the API:

JSON Profile Stock Quote AI Readiness Report
Origin Provenance
page leaf: f17a789589d005e05e8546a35d517a03a1298614f3a687921c4aa31f2f2e6aa3
parent: 50b63a69c6de1763557cef44b5e71b7b6dca0b0bc552ed9a530046a48cfa7815
content hash: 5c7434b1962c80d84e637268f3d102e710a473e4d913e9462ab1f4e710fde477
signed: 2026-04-13T04:46:46.287Z
sources: 8 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf